Macquarie Group
EBS icon

Macquarie Group’s Emergent Biosolutions EBS Stock Holding History

Macquarie Group’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,680
Closed -$18.3K – 1731
2024
Q2 		$18.3K Buy
+2,680
New +$11.5K ﹤0.01% 1635
2022
Q4 		– Sell
-465
Closed -$22K – 1862
2022
Q3 		$22K Sell
465
-562
-55% -$15.6K ﹤0.01% 2163
2022
Q2 		$32K Hold
1,027
– – ﹤0.01% 2171
2022
Q1 		$42K Hold
1,027
– – ﹤0.01% 2196
2021
Q4 		$45K Sell
1,027
-25,495
-96% -$1.15M ﹤0.01% 2187
2021
Q3 		$1.33M Hold
26,522
– – ﹤0.01% 1512
2021
Q2 		$1.67M Buy
26,522
+1,901
+8% +$122K ﹤0.01% 1469
2021
Q1 		$2.29M Buy
24,621
+2,798
+13% +$287K ﹤0.01% 1158
2020
Q4 		$1.96M Buy
21,823
+2,328
+12% +$214K ﹤0.01% 1108
2020
Q3 		$2.01M Sell
19,495
-7,684
-28% -$828K ﹤0.01% 1034
2020
Q2 		$2.15M Sell
27,179
-983
-3% -$73.3K ﹤0.01% 991
2020
Q1 		$1.63M Sell
28,162
-4,229
-13% -$244K ﹤0.01% 970
2019
Q4 		$1.75M Buy
32,391
+2,856
+10% +$155K ﹤0.01% 1077
2019
Q3 		$1.54M Sell
29,535
-1,359
-4% -$63.3K ﹤0.01% 1096
2019
Q2 		$1.49M Buy
30,894
+3,608
+13% +$173K ﹤0.01% 1103
2019
Q1 		$1.38M Buy
27,286
+3,600
+15% +$212K ﹤0.01% 1096
2018
Q4 		$1.4M Sell
23,686
-3,072
-11% -$198K ﹤0.01% 1058
2018
Q3 		$1.76M Sell
26,758
-4,699
-15% -$274K ﹤0.01% 1038
2018
Q2 		$1.59M Buy
31,457
+1,297
+4% +$67.6K ﹤0.01% 1059
2018
Q1 		$1.59M Sell
30,160
-8,867
-23% -$442K ﹤0.01% 1062
2017
Q4 		$1.81M Sell
39,027
-2,546
-6% -$107K ﹤0.01% 1054
2017
Q3 		$1.68M Buy
41,573
+15,604
+60% +$565K ﹤0.01% 1038
2017
Q2 		$881K Buy
25,969
+197
+0.8% +$6.08K ﹤0.01% 1198
2017
Q1 		$748K Sell
25,772
-728
-3% -$22.2K ﹤0.01% 1241
2016
Q4 		$870K Buy
+26,500
New +$794K ﹤0.01% 1194

Other funds holding EBS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
OHA
Oak Hill Advisors New York $701M AUM 78.4% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Macquarie Group's EBS Position: Q3 2024 in Review

Macquarie Group sold out of Emergent Biosolutions (EBS) in Q3 2024, closing a stake of 2,680 shares — an estimated $18.3K sold.

Macquarie Group first reported a position in EBS in Q4 2016 and held it in 25 quarters. The position peaked at $2.29M in Q1 2021. 140 funds tracked by Wall St. Rank hold EBS as of Q3 2024.

  • Macquarie Group reported no remaining Emergent Biosolutions position as of Q3 2024 after selling out during the quarter.
  • Macquarie Group sold 2,680 Emergent Biosolutions shares in Q3 2024, an estimated $18.3K.
  • Macquarie Group first reported a position in Emergent Biosolutions in Q4 2016 and held it in 25 quarters.
  • Macquarie Group's Emergent Biosolutions position peaked at $2.29M in Q1 2021.
  • 140 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2024.

Based on Macquarie Group's 13F filing for Q3 2024, filed 14 Nov 2024.